

Healthy for Life

Decoding the biology of aging to treat age-related diseases

Rejuvenate Biomed is an AI-enabled clinical-stage biotech company developing safe oral combination therapeutics that alter the course of age-related diseases

RJx-01: Advancing muscle health - unlocking value in sarcopenia


- Excellent safety and tolerability in humans, with a differentiated pharmacokinetic profile
- Clinical efficacy: significant improvements in muscle strength, function, and fatigue resistance in humans
- Transformative mechanism of action: boosted mitochondrial energy, reduced inflammation, and reversed fibrosis – tackling root causes of age-related muscle decline

Pipeline powered by innovation

- CombinAge® (AI platform) and CelegAge® (in vitro platform), enables rapid identification of synergistic, clinically translatable combinations
- Robust pipeline: multiple preclinical assets available for partnering across high-value indications
- Clinical Phase 2b data inflection points for disease-induced sarcopenia end 2026

How we generate value

Harnessing **clinically validated**, AI-enabled and **in vivo platforms**, we discover novel combinations to alter the course of age-related diseases



We build a pipeline of 'ready to partner' **novel combination drugs** for multiple indications with new formulations and strong IP protection

PROGRAM	INDICATION	DISCOVERY	PRECLINICAL	PHASE 1	PHASE 2
RJx-01	Disease-induced sarcopenia			<div style="background-color: #f96; width: 100%; height: 10px;"></div> COPD patients suffering from sarcopenia	
RJx-01	Treatment-induced sarcopenia			<div style="background-color: #f96; width: 100%; height: 10px;"></div> Obesity patients treated with GLP-1 RA	
RJx-01	Osteosarcopenia			<div style="background-color: #f96; width: 100%; height: 10px;"></div> Osteopenia and sarcopenia	
RJx-03/RJx-07	Non-disclosed	<div style="background-color: #f96; width: 100%; height: 10px;"></div> Undisclosed			

RJx-01 in Phase 2 clinical trials

- Disease-induced sarcopenia: Phase 2 trial **fully recruited** COPD patients with sarcopenia; results expected end 2026
- Treatment-induced sarcopenia: Phase 2 trial **upcoming**: muscle health protection during obesity treatment

Four critical success factors



We impact multiple aging pathways simultaneously by **developing combination drugs**



We employ our clinically **validated proprietary AI** and **in vivo platforms**, CombinAge® and CelegAge®



We start from **approved drugs with safety profiles** suitable for chronic use



We secure **strong patent protection**, both composition and medical applications & formulation

Let's connect

Health Campus Limburg, 3590 Diepenbeek, Belgium
 info@rejuvenatebiomed.com
 www.rejuvenatebiomed.com